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Abstract
Osteoarthritis (OA) is the most common joint condition and, with a burgeoning ageing population, is due to increase in 
prevalence. Beyond conventional medical and surgical interventions, there are an increasing number of ‘alternative’ therapies. 
These alternative therapies may have a limited evidence base and, for this reason, are often only afforded brief reference 
(or completely excluded) from current OA guidelines. Thus, the aim of this review was to synthesize the current evidence 
regarding autologous chondrocyte implantation (ACI), mesenchymal stem cell (MSC) therapy, platelet-rich plasma (PRP), 
vitamin D and other alternative therapies. The majority of studies were in knee OA or chondral defects. Matrix-assisted 
ACI has demonstrated exceedingly limited, symptomatic improvements in the treatment of cartilage defects of the knee and 
is not supported for the treatment of knee OA. There is some evidence to suggest symptomatic improvement with MSC 
injection in knee OA, with the suggestion of minimal structural improvement demonstrated on MRI and there are positive 
signals that PRP may also lead to symptomatic improvement, though variation in preparation makes inter-study comparison 
difficult. There is variability in findings with vitamin D supplementation in OA, and the only recommendation which can be 
made, at this time, is for replacement when vitamin D is deplete. Other alternative therapies reviewed have some evidence 
(though from small, poor-quality studies) to support improvement in symptoms and again there is often a wide variation 
in dosage and regimens. For all these therapeutic modalities, although controlled studies have been undertaken to evaluate 
effectiveness in OA, these have often been of small size, limited statistical power, uncertain blindness and using various 
methodologies. These deficiencies must leave the question as to whether they have been validated as effective therapies in 
OA (or chondral defects). The conclusions of this review are that all alternative interventions definitely require clinical trials 
with robust methodology, to assess their efficacy and safety in the treatment of OA beyond contextual and placebo effects.
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Introduction
Osteoarthritis (OA) is the most common form of arthritis 
and the global prevalence of knee OA alone is 3.8%, affect-
ing over 250 million individuals worldwide [1]. OA is an 
increasingly major socioeconomic and public health issue, 
with the years lived with disability increasing by 64% from 
1990 to 2010.
The current dogma is that OA may have differing causes 
but with a common, multi-tissue morphology including car-
tilage fibrillation, fissure and loss, subchondral bone changes 
and synovitis. OA is more prevalent in females than males 
and, although it can affect any joint, the most common ana-
tomical sites include the knee, distal interphalangeal joints 
and hip [2]. Clinically, OA is characterized by joint pain, 
significant stiffness and leads to functional decline and a 
reduced quality of life for the affected individual.
There are a number of different treatments for OA includ-
ing non-pharmacological and pharmacological approaches. 
Electronic supplementary material The online version of this 
article (https ://doi.org/10.1007/s4052 0-020-01515 -1) contains 
supplementary material, which is available to authorized users.
 * C. Cooper 
 cc@mrc.soton.ac.uk
Extended author information available on the last page of the article
 Aging Clinical and Experimental Research
1 3
However, despite a number of well-written and well-consid-
ered guidelines [3−6], there is no direct advice regarding the 
application of what may be termed ‘alternative’ treatments 
including autologous chondrocyte implantation (ACI), autol-
ogous/heterologous mesenchymal stem cells (MSCs), plate-
let-rich plasma (PRP), vitamin D and other therapies (e.g. 
oral collagens, methylsulfonylmethane, curcumin, ginger). 
This lack of appropriate clinical advice and information is 
an issue for clinicians when considering how best to advise 
patients, especially as some of these therapies have a high 
profile in the lay press.
A current literature review was, therefore, performed 
and a working group of the European Society for Clinical 
and Economic Aspects of Osteoporosis and Osteoarthritis 
(ESCEO) was convened to review, evaluate and summarize 
current evidence regarding these putative OA treatments, 
and to provide expert opinion on their current role in the 
treatment of OA. We have classified the alternative therapies 
into surgical and medical approaches.
Surgical therapy for cartilage loss
Joint replacement is an established surgical technique 
focused on treating the end-stage of OA. For this reason, 
more minor surgical procedures have been developed to 
be used in the case of localized, traumatic or early disease 
with the aim of regenerating cartilage and rejuvenating the 
joint. In this section, we examine the evidence for the use 
of autologous stem cell and cartilage therapies as potential 
treatment options.
Autologous chondrocyte implantation in knee 
cartilage defects
ACI has a 30 year history [7] and is an established tech-
nique for the treatment of ulcerated cartilage and carti-
lage defects. It involves an initial cartilage biopsy, from 
which chondrocytes are cultured in vitro. In a second sur-
gical procedure, a flap or membrane is then sutured (or 
glued) over the defect and the cultured chondrocytes are 
injected under this barrier. This process is summarized in 
Fig. 1. Over the last 10–15 years ACI has evolved (as bio-
engineering technology has improved) and now includes 
matrix-assisted ACI (MACI). The patient then undergoes 
very careful and graded rehabilitation to prevent the patch 
being dislodged.
Early randomised controlled trials (RCTs) data sug-
gested no significant benefit of ACI when compared to 
the alternative surgical option of microfracture [8] and 
although a histologic improvement was observed [9], 
the clinical relevance of this is questionable. Indeed a 
Cochrane review in 2011 concluded that there was insuf-
ficient evidence to recommend the use of ACI [10].
The method developed over time to include collagen-
covered ACI, and subsequently MACI, with the latter 
providing benefits including reduced size of the incision, 
greater surgical consistency, more consistent cell seeding, 
reduced periosteal hypertrophy and fewer adverse events 
[11−14].
Indeed, the matrix-applied method did perform sig-
nificantly better than microfracture in the SUMMIT study 
Fig. 1  A schematic demonstrat-
ing the process of autologous 
chondrocyte implantation. A 
chondral lesion is identified and 
a biopsy of non-articular carti-
lage is performed. The biopsy is 
cultured to amplify the number 
of chondrocytes. These are then 
injected under a periosteal flap 
(which is acquired from the 
proximal tibia)
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(an RCT of 144 patients over 2 years) [15] in terms of 
clinical and functional outcomes. There was however no 
significant benefit over microfracture in MRI or histologi-
cal outcomes. A key finding from these RCTs is that there 
was no correlation between the functional outcomes and 
evidence of structural repair when MRI is used, which is 
a potentially concerning finding.
ACI in combination with meniscal transplant allograft 
has good long-term outcomes with 75% still functioning 
well at 10-years (and 25% proceeding to arthroplasty). It is 
difficult to delineate whether the benefits of the procedure 
are due to ACI, meniscal transplant or indeed osteotomy 
(performed as part of the procedure) [16]. Similar results 
have been demonstrated in 57 patient with bipolar chon-
dral lesions in the tibiofemoral compartment [17] with 
75% having no radiographic progression at 10 years.
The cost of ACI and MACI are high, ranging from 
£4125 per patient to approximately £16,000 per MACI 
implant or £18,000 for a single vial of cells for ACI [18]. 
Therefore, in 2015 the technique was appraised by the 
National Institute for Health and Care Excellence (NICE) 
in the UK for the treatment of articular cartilage defects 
of the knee. The conclusions of this appraisal were that, 
while short-term clinical benefits were observed, the 
long-term clinical efficacy remained uncertain and the 
technique did not have robust evidence to demonstrate 
cost-effectiveness. Further research and evidence were 
recommended. The cost-effectiveness conclusions were 
considered harsh and were addressed in a consensus state-
ment by UK knee surgeons, who drew attention to the 
estimated cost-effectiveness of ACI being between £7000 
to £100,000 per Quality-Adjusted Life Year (QALY) (with 
the NICE threshold set at £20,000–30,000 per QALY).
There is a relative paucity of users, with, for example, 
only ten in the United Kingdom, which makes the develop-
ment of large-scale research a challenge. MACI remains a 
potentially fruitful avenue for symptomatic therapy in early 
cartilage disease and traumatic cartilage lesions, though cru-
cially not in OA.
Medical approaches
The scope of ‘non-surgical’ alternative therapies is large 
and, for this reason, this review focuses on the treatments 
which are likely to arise in clinical discussion with OA 
patients including autologous MSC injection, PRP, vitamin 
D and ‘other’ treatments.
Autologous mesenchymal stem cells
Articular cartilage is formed of a single cell type, the chon-
drocyte and a stable extracellular matrix that has no vascu-
lar, lymphatic or nervous supply. Subchondral bone provides 
mechanical and nutritional support and microfractures in 
this tissue can result in the release of undifferentiated mes-
enchymal stem cells (MSCs) from the bone marrow to facili-
tate the repair of chondral defects.
The repair capacity of MSCs has led to the development 
of techniques to directly inject MSCs locally into the joint 
following the ex vivo preparation of mesenchymal cells 
(Fig. 2). MSCs (also known as human or bone marrow 
stromal cells, multi-potent adult stem cells, mesenchymal 
progenitor cells and skeletal stem cells) have the ability 
to differentiate into the three tissue types, cartilage, bone 
and fat, and are invested, by definition, with an innate 
capacity for self-renewal and rapid proliferation. MSCs 
Fig. 2  A depiction of the inject-
able and implantable options 
for delivery of MSCs and the 
potential sources of MSCs 
which are appropriate for each 
method
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display paracrine anti-inflammatory and immunomodula-
tory properties [19, 20] and can be harvested from bone 
marrow (biopsy or aspirate) as well as from the stromal 
vascular fraction in adipose tissue. (Table 1) Autologous 
sources avoid any immunological concerns, however, there 
is concern that, as MSCs are cleared from the joint rapidly, 
the joint may simply be experiencing the benefits afforded 
by a ‘wash-out’.
The use of MSCs in OA is an area of burgeoning research 
and, at the time of writing, there were 182 studies recorded, 
in various states of progress and 3 systematic reviews which 
best address the use of stem cells in the treatment of OA 
[21−23].
The review performed by Hached and colleagues ana-
lysed a total of 44 trials of intra-articular injection of MSCs 
in the treatment of OA including bone marrow-derived, 
adipose tissue-derived and umbilical cord MSCs [21]. The 
review concluded that all three methods of acquisition of 
MSCs had evidence to support their use in the treatment of 
OA and that intra-articular injection of these cells was safe 
with very few side effects. An extensive review appraised 
20 full-text records including systematic reviews, compre-
hensive reviews, clinical reviews and meta-analyses pub-
lished between 2006 and 2016 which addressed the treat-
ment of cartilage lesions with MSCs [23]. In their review, 
the authors noted that improvements in symptoms (pain and 
function) were more commonly reported than structural/tis-
sue improvement. There was a low level of evidence for the 
intervention with a mere 25 items of Level I graded evidence 
and subsequently concluded that it was “unclear” if stem 
cells were an effective treatment for OA. Broadly, stem cell 
therapies were effective in symptomatic (pain) relief related 
to chondral defects and defects (or lesions) due to OA. The 
authors reported, overall, limited repair and integration with 
extensive variability in the results presented. The main issues 
recorded included significant variability in MSC sources, 
techniques for preparation, methods of administration and 
the range of co-interventions used (including micro-fracture, 
sub-chondral drilling, debridement, PRP).
There are very few studies which have demonstrated 
any degree of structural improvement in knee OA. Lamo-
Espinosa and colleagues [24], reported the results of an 
RCT of increasing doses (10 × 106 or 100 × 106) of bone 
marrow MSC, intra-articular injection against hyaluronic 
acid injection in 30 patients with OA (Kellgren–Lawrence 
grades II–IV). Participants were followed-up for 12 months 
and those in the MSC injection group had significant 
improvements in functionality and symptoms. Interest-
ingly, only those in the high dose MSC injection group had 
statistically significant structural improvement in cartilage 
thickness on MRI at 12 months, opening the possibility 
of a dose–response. It should be noted that the inclusion 
of patients with such severe disease (Kellgren–Lawrence 
IV) suggests that the experimental group was substantially 
heterogeneous.
A pilot study by Orozco and colleagues [25] performed 
on patients with mild to severe knee OA (Kellgren–Law-
rence grades II–IV) who received an intra-articular injec-
tion of (40 × 106) bone marrow-derived MSCs, demonstrated 
improvement in pain, function and cartilage quality at 
12 months. The pain relief was maintained at 2 years, while 
the objective cartilage improvement (on MRI) continued on 
a trajectory of improvement at 2 years [26]. However, it must 
be noted that this study only included 12 patients and so 
conclusions should be tentative at best.
Allogeneic MSC injection was demonstrated to be both 
feasible and safe, as reported in previous studies [27], though 
the observed negative outcomes include the generation of 
fibrocartilage, injection-related pain and swelling, infec-
tion post-bone marrow aspirate and a pulmonary embolus 
2 weeks post-bone marrow aspirate [23]. In a further system-
atic review, only 2 serious adverse events (synovial effusion 
and unstable angina) were observed amidst 288 patients.
Table 1  A summary of the advantages and disadvantages in OA therapy of MSCs acquired from different sources, including; bone marrow, adi-
pose tissue and stromal vascular fraction, the synovial membrane, umbilical cord and peripheral blood, synovial fluid and amniotic fluid
MSCs Cell source Advantages Disadvantages
Bone marrow (bone marrow conc. and bone mar-
row aspirate conc.)
High chondrogenic potential
Relative ease of collection
High variability in MSC number
MSC numbers and quality decline with age
Adipose tissue and stromal vascular fraction Ease of harvest
Large amount of tissue can be extracted
Limited donor site morbidity
MSC numbers decline with obesity
Lower chondrogenic potential
Synovial membrane High chondrogenic potential
Lowest osteogenic potential among MSCs
Limited number
Umbilical cord MSCs Major source of allogeneic cells
Ease of harvest
Unlimited numbers
Chondrogenic potential variable
Peripheral blood, synovial fluid, amniotic fluid Relative ease of collection High variability in MSC numbers
Chondrogenic potential variable
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Pers and colleagues studied three dosages of adipose tis-
sue-derived MSCs (2 × 106, 10 × 106, 50 × 106 cells) in the 
Adipose Derived mesenchymal stromal cells in Patients with 
knee Osteoarthritis (ADIPOA) trial and found 2 × 106 was 
optimal in terms of functionality and pain relief at 9 months 
[28] and postulated MSCs may operate via innate and adap-
tive immune modulation [29]. This phase I trial is now in 
phase II (ADIPOA-2) and recruitment of 150 patients is 
underway.
Limitations and barriers to the routine application of 
MSCs for OA from this plethora of clinical studies were a 
consequence of (i) significant variation in MSC source, (ii) 
significant variation in MSC preparation protocols adopted, 
(iii) significant variation in MSC delivery approaches 
adopted and, (iv) significant variation in the number of 
different co-interventions with MSCs including micro-
fracture, sub-chondral drilling, debridement, and PRP as 
well as hyaluronic acid, albumin and serum, osteophyte 
removal, and surgical interventions (ACL repair and high 
tibial osteotomy).
Nevertheless, the following factors were associated with 
increased efficacy of MSC injection for OA:
• Younger age
• Male gender
• Low BMI
• Small lesion/defect
• Early/mild to moderate OA severity
It should also be considered that these MSC treatments 
are currently not covered by many health insurance provid-
ers and the costs are high. For example, in the United States, 
the cost of a single stem-cell treatment for osteoarthritis was 
estimated at $5156 (95% CI $4550–5762) based on data 
from 273 centers [30].
In conclusion, the predominantly poor-quality, current 
literature suggests that symptoms, particularly pain, may 
improve with MSCs injection, however, evidence of struc-
tural improvement is unconvincing and positive effects 
appear to be observed in particular patient phenotypes. The 
overwhelming conclusion is a need to standardize the inter-
vention if progress is to be made (Table 2). There is also a 
substantial need for phase II and III trials with the results of 
ADIPOA-2 being keenly awaited.
Platelet‑rich plasma
Platelets play an important role in coagulation but also 
inflammation and PRP is a therapy which has been used 
extensively in equine tendinopathy [31] and has been inves-
tigated in the treatment of OA, particularly of the knee [32].
Platelet-rich plasma is a fluid which is rich in growth 
factors that stimulate cell proliferation, cellular migration, 
angiogenesis and the synthesis of the extracellular matrix 
including; platelet-derived growth factor (PDGF), tumor-
like growth factor-β (TGF-β), fibroblast growth factor 
(FGF), vascular endothelial growth factor (VEGF), hepato-
cyte growth factor (HGF) and insulin-like growth factor-1 
(IGF-1).
It is derived through centrifugation of a patient’s blood, 
with the aim of separating a plasma component which is 
rich in platelets (> 95% platelets) from whole blood which 
is poor in platelets (4% platelets). The PRP is then extracted 
and injected into the affected joint. The intricacies of prepa-
ration techniques vary and result in significantly different 
constituent cells (erythrocyte and leucocyte proportions), 
platelet concentrations and injection volumes [33] (Fig. 3). 
Indeed, there is a global schism in practice with Europe-
ans preferring to use leukocyte-poor and Americans using 
leukocyte-rich PRP. PRP has been investigated in RCTs [34, 
35] but the broad variation in preparation methods makes 
inter-trial comparison difficult and robust conclusions harder 
to ascertain and few are blinded. To emphasize this point 
we have synthesized and summarized some of the seminal 
studies below.
The issues surrounding the preparation of PRP are cov-
ered in a review of the techniques utilised in a number of 
RCTs and systematic reviews [36]. There is substantial 
Table 2  A synthesis of the main issues in MSC efficacy in the treatment of OA and limitations to adequate assessment through clinical trials
Key factors for stem cell efficacy in OA Key factors limiting stem cell efficacy and clinical trial interpretation of 
MSC use in OA
• Age (younger patients typically display better outcomes)
• Gender (males typically better outcomes compared to female coun-
terparts)
• BMI (lower BMI is associated with better outcomes)
• Lesion or defect size (better repair associated with smaller lesion 
size)
• Stage of OA (early OA, mild to moderate OA correlated with better 
outcomes)
• Significant variation in MSC source
• Significant variation in MSC preparation protocols
• Variation in MSC Delivery
• Significant variation in the number of different co-interventions with 
MSCs
 Micro-fracture, sub-chondral drilling, debridement, and platelet rich 
plasma
 Less common—hyaluronic acid, albumin and serum, osteophyte 
removal, and surgical interventions (ACL repair and high tibial oste-
otomy)
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variation in techniques including; the subject studied 
(severity of knee OA), PRP preparations, the inclusion of 
leukocytes, platelet count, number of injections delivered, 
interval/frequency of administration, volume of injection, 
whether fresh or freeze-thawed PRP were used, the use of 
anticoagulants and activating agents, separation techniques 
and any co-administered injections. With this in mind, a 
technical analysis was performed in 2017 to evaluate the 
similarities and differences between differing PRP formu-
lations, in an attempt to determine the best preparation for 
the treatment of knee OA.
Filardo and colleagues [37, 38] performed a blinded 
trial in which they recruited participants with radiographic 
knee OA up to a Kellgren and Lawrence score of ≤ III, 
with 96 randomised to PRP and 96 to hyaluronic acid as 
a comparator. The PRP was centrifuged twice and PRP 
participants received 3 injections, once a week for three 
weeks and all participants were followed up for 12 months 
initially but extending to 5 years [39]. The key finding 
was that both treatments were equally effective in reducing 
knee OA symptoms and improving function over time but 
leucocyte-rich PRP was no more effective than hyaluronic 
acid.
To summarize the available evidence regarding PRP a 
number of systematic reviews have been performed [40−42]. 
PRP provided significant improvements in knee OA patient 
outcomes at 12  months and larger improvements were 
observed in those with milder radiographic disease (Kell-
gren and Lawrence ≤ II) [40],
Significant improvements in ‘patient recorded outcomes’ 
were also observed with PRP as opposed to hyaluronic 
acid at 3–6 months (WOMAC 28.5 vs. 43.4 respectively, 
p = 0.0008) and 6–12  months (WOMAC 22.8 vs. 38.1, 
p = 0.0062) [41].
A further systematic review published in 2018 (includ-
ing 7 randomized placebo-controlled trials and 908 patients) 
sought to investigate the superiority of PRP over hyaluronic 
acid which was not demonstrated. In respect of PRP the min-
imal clinically important difference (MCID) was observed in 
5 of the 7 papers, and suggested that differences in clinical 
outcomes could be due to variation in the preparation of PRP 
in terms of; centrifugation (speed, frequency, time-length, 
activating agents), administration (frequency, volume of 
injection) and post-administration rehabilitation protocols 
[42]. From a safety point of view, no local or systemic seri-
ous adverse events were noted in the reviewed articles.
Milants and colleagues used a previous definition of 
minimal clinically important improvement in pain (MCII) 
to determine whether an observed difference had any ‘mean-
ingful’ effect in clinical practice. This was set at 15 out of 
100 for absolute improvement and 20% for relative improve-
ment for knee OA, as defined by Tubach et al. [43].
The Milants technical analysis included 19 RCTs, and 
studies were classified into two groups depending on out-
comes with a ‘bad responder group’, defined as a response 
less than the minimal clinically important improvement 
(MCII) (n = 4 studies), and a ‘very good responder group’, 
defined as a response greater than twice the MCII (n = 7 
studies). The reviewers contacted authors of the trials to 
obtain information regarding the preparation which was 
missing from the manuscript and PRP preparation was clas-
sified according to the Mishra (a classification in which PRP 
is divided into 4 types depending on 3 variables; white blood 
cells: increased or minimal, activation: yes or no, platelet 
content > 5 times patient baseline or ≤ 5 times patient base-
line) and PAW (Platelet concentration, Activation prior to 
injection, White blood cell content).
In almost all studies with a very good responder group, 
PRPs were leukocyte-poor, activated prior to injection and 
platelets < 5 times baseline or between baseline and 750,000 
platelets/µL), administered according to a lower number 
of injections (1 or 2 rather than 3), with a longer interval 
between injections (2 to 3 weeks per injection rather than 
once weekly) and a single (as opposed to double) spinning 
technique. The use of leukocyte-rich PRP was only found in 
the bad responder group. The use of calcium chloride and 
citrate was common in the very good responder group.
The cost of the PRP procedure is estimated at $714 (95% 
CI $691–737) based on data from 179 centers from across 
the United States [44].
In conclusion, although PRP may have repeated mild 
symptomatic benefits, there is yet to be experimentally 
robust demonstration of symptomatic and structural effects 
in the current literature. Research is required to better under-
stand the mechanism of action, including investigation of the 
survival and location of platelet-derived factors within the 
joint following injection. In order for PRP to be considered 
Fig. 3  A comparison of platelet concentration and volume of protein-
rich plasma (PRP) resulting from the extraction methods employed by 
5 laboratories. [33]
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within the dogma of recommended treatment for OA, at least 
one large, randomized, placebo-controlled trial and further 
investigation regarding preparation and dosage efficacy is 
required. This working group cannot, therefore, make a rec-
ommendation to use PRP as an intervention for OA.
Vitamin D
There is a secular trend toward decreased vitamin D lev-
els, with serum concentrations averaging 49 ng/mL in the 
mid-twentieth century to approximately 23 ng/mL now, and 
with over a billion individuals being vitamin D deficient 
or insufficient [45]. Due to the role played by sunlight in 
the in vivo production of vitamin D, particularly low levels 
are observed at the extremes of latitude [46], and in winter 
months. Studies of seasonal gene expression have shown 
that some pro-inflammatory factors, including soluble IL-6 
receptor and C-reactive protein have a peak expression in 
winter months and vitamin D receptor expression peaks in 
the summer months [47]. It is, therefore, interesting that 
certain diseases display similar seasonality and geography, 
including OA. This descriptive epidemiological observation 
is supported by basic scientific findings including [48]:
• There are receptors for vitamin D on chondrocytes which 
may play a role in the regulation of matrix metallopro-
teinases and prostaglandin E2 production
• Vitamin D stimulates proteoglycan synthesis in mature 
chondrocytes
• Vitamin D deficiency influences bone remodeling which 
may predispose to the development of OA
Despite these observations, four RCTs of vitamin D in 
OA have been performed in the United States (US) [49], 
India [50], the United Kingdom (UK) [51] and Australia 
[52]. None of these have demonstrated structural or symp-
tomatic benefit in OA.
The pilot study performed in India [50] included 103 par-
ticipants (59.4% females) with a baseline age of approxi-
mately 50 and a baseline 25-OH vitamin D of < 20 ng/mL. 
They found a significant reduction in knee pain and improve-
ment in function but no significant alteration in radiographic 
knee OA at 12 months.
The placebo-controlled trial performed by McAlindon 
and colleagues [49] (in the US) included 146 female partici-
pants with a mean age at baseline of 62.4 years. At two years 
they found no improvements in knee symptoms, functional 
status or cartilage structure with vitamin D.
In the aforementioned UK placebo-controlled trial [51], 
despite an increase in serum 25-hydroxy-vitamin D (from 
approximately 20 to 30 µg/L) in the treatment group, no 
significant changes in symptomatic or radiographic knee 
OA were observed after 3 years in 474 participants (over 
the age of 50).
In Australia, Jin and colleagues demonstrated that in 209 
patients with low vitamin D (12.5–60 nmol/L) treated for 
2 years with monthly oral vitamin D3 (50,000 IU), there was 
no significant improvement in MRI-measured tibial cartilage 
volume or WOMAC knee pain score [52].
The relationship between vitamin D and knee OA has 
been investigated in a recent systematic review of 11 stud-
ies, which concluded that although vitamin D deficiency 
is associated with knee OA, the evidence regarding this 
association is inconsistent [53]. The studies included in the 
review were largely of cohort and cross-sectional design 
but also included two RCTs. The systematic review demon-
strated that there was marked variation in the relationships 
between vitamin D and OA with a level of evidence (for an 
association of vitamin D deficiency with prevalent sympto-
matic knee OA) of ‘moderate’, while the relationship with 
prevalent radiographic knee OA was graded as ‘limited’. 
This negative conclusion supports that of a prior systematic 
review [54].
It should be acknowledged that vitamin D deficiency has 
been associated with a range of co-morbidities, of which OA 
is only one. However, the adverse effect profile of the supple-
ment is favorable and should be strongly considered in those 
at risk of deficiency. Should there be systematic screening 
for vitamin D deficiency or systematic supplementation of 
vitamin D? This question is beyond the purview of this arti-
cle and is dependent on many factors which are related to 
local healthcare systems and economic considerations.
We conclude by recommending that, when severe defi-
ciency is diagnosed (especially in winter), vitamin D should 
be supplemented through the evidence that such supplemen-
tation ameliorates OA symptoms is inconclusive.
Other medical therapies
It should be noted that the medical therapies included in this 
section are very rarely mentioned in international guidelines, 
however, they are often the subject of discussions between 
patients and clinicians. Collagens, methylsulfonylmethane, 
S-adenosylmethionine, curcuma, harpagophytum and ginger 
are commonly used in the treatment of OA in many coun-
tries [55], with polyphenols, green tea, ‘Cat’s claw’ and 
dairy products also being mentioned.
Collagens: oral and intra‑articular
Oral collagens are a rich source of amino acids, and, in OA, 
are purported to stimulate the joint to produce endogenous 
collagens in response to supplementation.
In 2016 a study investigated 190 patients, randomised to 
receive undenatured type II collagen (40 mg) or glucosamine 
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hydrochloride and chondroitin sulfate or placebo [56]. The 
primary outcome was total WOMAC change from baseline 
with secondary outcomes being Lequesne index and pain 
VAS. After 6 months they found that undenatured type II 
collagen led to a significantly greater reduction in WOMAC 
compared to placebo (551 vs. 414, p = 0.002) and compared 
to the glucosamine and chondroitin sulfate arm (551 vs. 454, 
p = 0.009). In terms of secondary outcomes, there was a 
greater reduction in Lequesne index (2.9 vs. 2.1, p = 0.009).
A further RCT investigated the performance of 5, once 
weekly 4 mL injections of polymerized collagen type I (of 
porcine origin) compared to sodium hyaluronate with assess-
ments at 3 and 6 months [57]. The primary outcome was 
Lequesne index (measuring the severity of knee OA) at the 
3 month time point with a visual analogue score for pain and 
SF-36 questionnaire also recorded. They found no significant 
differences between the groups for the above outcomes at 
either 3 or 6 months.
Gelatin, a form of collagen-rich in proline, was assessed 
in 52 patients as part of a randomised, placebo-controlled 
trial which found significant inter-group differences in sev-
eral types of pain, however, an effect size was not reported, 
making extrapolation to clinical benefit difficult [58]. Unde-
natured collagen, an alternative form of collagen, was com-
pared to glucosamine and chondroitin with 26 patients per 
group. This found no inter-group differences in the efficacy 
of the interventions [59].
In 2012, Van Vijven and colleagues published a system-
atic review of a variety of oral collagens at various doses 
comprised of 8 trials of collagen hydrosylates (3 versus pla-
cebo), gelatin (1 versus placebo) or undenatured collagen 
(versus glucosamine hydrochloride and chondroitin sulfate) 
[58]. The review concluded that there was ‘low’ grade evi-
dence for the use of these in OA. Those treated with collagen 
hydrosylates included 313 treated patients (taking 10 g per 
day) against 297 on a placebo preparation and found a sig-
nificant effect on symptoms (WOMAC pain (− 0.48) with a 
significant but small effect size of 0.17) but no effect on the 
joint structure as assessed by MRI scan.
There are various preparations of oral or intra-articular 
collagens. Although widely used in a large number of coun-
tries, current data do not support a positive recommendation 
to treat OA patients despite a mild effect on symptoms (pain) 
and function.
Methylsulfonylmethane (MSM)
This dietary supplement is found in plants, fruits and veg-
etables, and can be taken alone or in combination with 
other supplements. There have been two, notable, placebo-
controlled trials of MSM in patients with knee OA, both 
in approximately 50 patients over 12 weeks of follow-up. 
The first [60] involved a dosage schedule which resulted 
in 6 g per day and demonstrated a significant improvement 
in SF-36, WOMAC pain and function in the MSM group 
(p < 0.05). The second involved a dose of approximately 3 g 
per day demonstrated a significant improvement in WOMAC 
function but not in WOMAC pain or SF-36 compared to 
placebo [61].
A trial in knee OA randomised 118 patients between glu-
cosamine, MSM, combination therapy or placebo and found 
a significant improvement in pain and Lequesne functional 
index at 12 weeks in all groups except the placebo arm.
A recent RCT examined the performance of glucosamine 
and chondroitin in combination with MSM versus glucosa-
mine and chondroitin alone and versus placebo, in a popula-
tion of 147 early knee OA patients (Kellgren and Lawrence 
grade I-II). This study demonstrated improvement in the 
groups which included MSM compared to the other treat-
ment groups, in terms of pain VAS and WOMAC scores 
[62].
In conclusion, small trials did not demonstrate any major 
safety concerns for MSM treatment. Whether there is a 
symptomatic benefit over a short follow-up period is a ques-
tion which would need to be answered through larger, well-
designed trials and long term follow-up data are required.
S‑adenosylmethionine (SAMe)
This is a substance produced from methionine in the liver. 
The treatment of hip and knee OA with SAMe was the sub-
ject of a Cochrane review of 4 randomised, placebo-con-
trolled trials [63]. This review included 656 patients and 
demonstrated a significant improvement with SAMe com-
pared to placebo but with a very minor effect on pain (4 mm 
on a 100 mm VAS) and function (2 mm on a 100 mm VAS), 
which are of questionable clinical significance. There was no 
significant difference in adverse effects or withdrawals but it 
should also be noted that the methodological and reporting 
quality were poor and that there was a moderate degree of 
inter-trial heterogeneity (I2 = 54%).
Curcuma
Curcuma (or curcumin) is an extract of turmeric, a yel-
low spice, and member of the ziangiberaceae family. Both 
curcuma and ginger have roots in Ayurvedic and Chinese 
medicine [64] with curcuma manifesting an anti-inflam-
matory effect via cyclo-oxgenase (COX)-2, prostaglandins 
and leukotoxin inhibition. There is a wide variation in daily 
doses from 180 to 2000 mg, which makes direct, inter-study 
comparison problematic. Nevertheless, a meta-analysis was 
published in 2016 included 4 placebo-controlled trials in the 
context of knee OA; 2 trials versus ibuprofen and 1 versus 
diclofenac. In these trials of curcuma, improvements were 
seen in symptomatic measures and NSAID consumption (up 
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to 4 months) versus placebo but no significant superiority 
was noted versus ibuprofen or when added to diclofenac.
Although a few, idiosyncratic adverse effects were 
reported in the trials, the meta-analysis concluded that cur-
cuma could be considered safe at daily doses of 4800 mg 
for 4 months [65].
A more recent meta-analysis, published in 2018, included 
11 RCTs (N = 1009 patients) investigating the role of curmi-
noids and boswellia (a gum-resin used in Ayurvedic medi-
cine) in the treatment of knee OA [66]. There was some 
improvement in pain and function outcomes versus placebo, 
however, the conclusion was that evidence was currently too 
scant to allow the therapies to be included in clinical recom-
mendations for treatment.
A trial of bio-optimized curcuma in the treatment of knee 
OA was reported in 2019 [67]. After 3 months of treatment, 
there were no statistical differences in intention to treat 
analyses for curcuma efficacy comparing the treatment to 
placebo arms for the co-primary endpoints (which are not 
included in those recommended by the European Medi-
cines Agency or scientific societies). However, there was 
a significantly higher incidence of diarrhea in the curcuma 
group. In summary, experimental data regarding curcuma 
is sparse. The little evidence there supports a mild effect on 
OA symptoms. The sample sizes of the published trials are 
small, follow-up is short [65] and longer-term, robust studies 
are required before curcumin can be actively recommended 
from an efficacy stand-point.
Harpagophytum
Also known as ‘Devil’s claw’ Harpagophytum is an African 
plant which is thought to manifest anti-inflammatory effects, 
similar to curcuma, via inhibition of COX-2 and leukotoxin. 
A systematic review by Gagnier and colleagues investigated 
the role of Harpagophytum in the treatment of lower back 
pain and OA, including 3 randomised, placebo-controlled 
trials of hip and knee OA (385 patients) [68]. This review 
concluded that there was ‘moderate’ evidence of effective-
ness for the use of 60 mg of harpagophytum powder, though 
longer, higher-quality trials are required before it can be rou-
tinely recommended in clinical practice.
Ginger
Ginger, another member of the ziangiberaceae family, is 
thought to manifest anti-inflammatory effect via inhibition 
of COX, lipoxygenase, reduction in tumor necrosis factor 
and inflammatory prostaglandin production. There are data 
to suggest that ginger extract (Zintona EC®) is superior to 
placebo in terms of pain relief at 6 months (though efficacy 
was the same at 3 months) in a double-blind, randomised, 
placebo-controlled, crossover trial of knee OA [69].
Additionally, trials have demonstrated improvements 
in pain and mobility and reduced rescue medication usage 
intake versus placebo, though with more (mostly mild) gas-
trointestinal adverse events [70].
In 2015, the trial data were summarized and analyzed 
in a systematic review and meta-analysis of 5 randomised 
placebo-controlled trials, totaling 593 patients, which found 
a significant reduction in pain and disability with ginger. 
However, twice the rate of discontinuation was observed 
with ginger versus placebo (Relative Risk 2.33, 95% CI 
1.04–5.22) [71]. A similar finding was reported in an earlier 
systematic review which noted “infrequent reports of mild, 
and predominantly gastrointestinal, adverse effects” [72].
Conclusion
In this review, we have synthesized the current evidence 
regarding alternative therapies for OA. Our findings are 
summarised in Table 3. Publication bias may be an issue 
with this group of treatments, however, this is not always 
the case (as seen throughout this review).
In summary, for all of the interventions covered in this 
review, issues of study design limit the degree to which 
inference can be made about clinical effectiveness in symp-
tomatic OA. It is clear that none of these would currently 
clear the required hurdle for regulatory approval, were they 
to be assessed in like manner to current pharmaceutical 
interventions. However, there is also an insufficient basis 
for declaring them completely ineffective. They, therefore, 
remain an area in which further, appropriately designed, 
large, blinded, RCTs are an urgent necessity.
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Table 3  A summary table of the key, take-home points for each of the interventions reviewed
Alternative therapy Key points
Autologous chondrocyte implantation • Treatment for cartilage defects and not osteoarthritis
• Includes ACI and MACI
• Trial evidence to support symptomatic benefit
• Supported by NICE in the UK for specific patient group (including no previous knee surgery, limited 
evidence of knee osteoarthritis, large chondral defect)
Mesenchymal stem cell injection • There are multiple sources of MSCs with differing profiles of usage and limitations
• Multiple sources of MSCs lead to difficulties in directly comparing clinical trials
• Trial evidence to support symptomatic benefit
• Limited evidence to support structural benefit (MRI cartilage thickness)
Platelet-rich plasma • Trial evidence to support symptomatic benefit
• Multiple methods of preparation lead to difficulties in directly comparing clinical trials
Vitamin D • Evidence of efficacy in clinical trials is equivocal
• Recommendation to provide supplementation to those patients with evidence of depleted levels of 
25OH-vitamin D
Other alternative therapies • Very limited clinical trial data to suggest the efficacy of oral collagens, MSM, SAMe, curcuma and 
ginger
• Adverse events: largely rare, though ginger appears to be associated with an increased risk of mild 
gastro-intestinal adverse events
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